Trv Gp Iv LLC Takes $66.87 Million Position in Maze Therapeutics, Inc. (NASDAQ:MAZE)

Key Points

• Trv Gp Iv LLC has acquired a significant position in Maze Therapeutics, purchasing approximately $66.87 million worth of shares, which makes up about 72% of its portfolio.
• Maze Therapeutics received a positive outlook from analysts, with five rating the stock as a buy and setting an average target price of $25.60.
• The company's stock is currently trading at $14.25, down 1.8%, and reported earnings of ($1.15) per share, which missed analyst estimates.

Trv Gp Iv LLC purchased a new position in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 6,073,958 shares of the company's stock, valued at approximately $66,874,000. Maze Therapeutics accounts for about 72.0% of Trv Gp Iv LLC's portfolio, making the stock its biggest holding. Trv Gp Iv LLC owned about 13.87% of Maze Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also bought and sold shares of the business. Alphabet Inc. bought a new stake in Maze Therapeutics during the first quarter worth about $26,561,000. General Catalyst Group Management LLC acquired a new position in shares of Maze Therapeutics in the 1st quarter valued at approximately $11,405,000. Harvard Management Co. Inc. acquired a new position in shares of Maze Therapeutics in the 1st quarter valued at approximately $7,019,000. Bessemer Group Inc. bought a new stake in shares of Maze Therapeutics during the 1st quarter worth approximately $5,305,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in shares of Maze Therapeutics during the 1st quarter worth approximately $796,000.

Wall Street Analysts Forecast Growth

Several brokerages have commented on MAZE. HC Wainwright assumed coverage on shares of Maze Therapeutics in a research report on Wednesday, July 23rd. They set a "buy" rating and a $34.00 price objective for the company. Wedbush started coverage on Maze Therapeutics in a research note on Tuesday, July 8th. They issued an "outperform" rating and a $17.00 price target on the stock. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $25.60.

Maze Therapeutics Stock Down 1.8%

MAZE stock opened at $14.25 on Thursday. The stock's 50 day moving average is $13.82. Maze Therapeutics, Inc. has a 1 year low of $6.71 and a 1 year high of $19.19.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($1.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.39).

Maze Therapeutics Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.